Literature DB >> 27048835

Probiotics and respiratory and gastrointestinal tract infections in Finnish military conscripts - a randomised placebo-controlled double-blinded study.

K Kalima1,2, L Lehtoranta3, L He4, J Pitkäniemi4,5, R Lundell6, I Julkunen7,8, M Roivainen7, M Närkiö9, M J Mäkelä10, S Siitonen1, R Korpela3, A Pitkäranta2,6.   

Abstract

Military conscripts are susceptible to respiratory and gastrointestinal tract infections. In previous studies probiotics have shown potency to reduce upper respiratory and gastrointestinal infections. The aim was to study whether probiotic intervention has an impact on seasonal occurrence of upper respiratory and gastrointestinal infections in two different conscript groups. In a randomised, double-blinded, placebo controlled study (https://clinicaltrials.gov NCT01651195), a total of 983 healthy adults were enrolled from two intakes of conscripts. Conscripts were randomised to receive either a probiotic combination of Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis ssp. lactis BB12 (BB12) or a control chewing tablet twice daily for 150 days (recruits) or for 90 days (reserve officer candidates). Clinical examinations were carried out and daily symptom diaries were collected. Outcome measures were the number of days with respiratory and gastrointestinal symptoms and symptom incidence, number and duration of infection episodes, number of antibiotic treatments received and number of days out of service because of the infection. Statistically no significant differences were found between the intervention groups either in the risk of symptom incidence or duration. However, probiotic intervention was associated with reduction of specific respiratory infection symptoms in military recruits, but not in reserve officer candidates. Probiotics did not significantly reduce overall respiratory and gastrointestinal infection morbidity.

Entities:  

Keywords:  Bifidobacterium; Lactobacillus; military medicine

Mesh:

Year:  2016        PMID: 27048835     DOI: 10.3920/BM2015.0172

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  2 in total

1.  Fewer Community-Acquired Colds with Daily Consumption of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2. A Randomized, Placebo-Controlled Clinical Trial.

Authors:  Irini Lazou Ahrén; Magnus Hillman; Elisabet Arvidsson Nordström; Niklas Larsson; Titti Martinsson Niskanen
Journal:  J Nutr       Date:  2021-01-04       Impact factor: 4.798

2.  Clinical Outcomes of Standard Triple Therapy Plus Probiotics or Concomitant Therapy for Helicobacter pylori Infection.

Authors:  Jae Hyun Jung; In Kuk Cho; Chang Hee Lee; Gwan Gyu Song; Ji Hyun Lim
Journal:  Gut Liver       Date:  2018-03-15       Impact factor: 4.519

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.